OraSure Technologies, Inc. (NASDAQ:OSUR) Director Mara G. Aspinall acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, with a total value of $71,150.00. Following the completion of the acquisition, the director now owns 5,000 shares in the company, valued at approximately $71,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OraSure Technologies, Inc. (NASDAQ:OSUR) opened at $14.25 on Friday. The company has a market cap of $864.23, a price-to-earnings ratio of 27.40, a P/E/G ratio of 2.74 and a beta of 1.39. OraSure Technologies, Inc. has a 52-week low of $7.84 and a 52-week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. The business had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company’s revenue was up 31.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.11 EPS. analysts expect that OraSure Technologies, Inc. will post 0.42 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “OraSure Technologies, Inc. (OSUR) Director Purchases $71,150.00 in Stock” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/orasure-technologies-inc-osur-director-purchases-71150-00-in-stock/1697914.html.

Several research firms recently commented on OSUR. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Canaccord Genuity increased their target price on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, September 20th. Jefferies Group LLC cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. OraSure Technologies currently has an average rating of “Buy” and a consensus price target of $18.21.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in shares of OraSure Technologies by 127,593.4% during the 1st quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after purchasing an additional 7,737,261 shares in the last quarter. Daruma Capital Management LLC boosted its stake in shares of OraSure Technologies by 2,761.0% during the 2nd quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after purchasing an additional 2,722,886 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of OraSure Technologies by 30.3% during the 1st quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after purchasing an additional 1,037,439 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of OraSure Technologies by 175.6% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock valued at $20,214,000 after purchasing an additional 572,397 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of OraSure Technologies by 32.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after purchasing an additional 452,642 shares in the last quarter. 92.56% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.